Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment

Approximately 15% of patients with coronavirus disease 2019 (COVID-19) experience severe disease, and 5% progress to critical stage that can result in rapid death. No vaccines or antiviral treatments have yet proven effective against COVID-19. Patients with severe COVID-19 experience elevated plasma...

Descripción completa

Detalles Bibliográficos
Autores principales: Yeleswaram, Swamy, Smith, Paul, Burn, Timothy, Covington, Maryanne, Juvekar, Ashish, Li, Yanlong, Squier, Peg, Langmuir, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Inc. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308779/
https://www.ncbi.nlm.nih.gov/pubmed/32585295
http://dx.doi.org/10.1016/j.clim.2020.108517

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308779/
https://www.ncbi.nlm.nih.gov/pubmed/32585295
http://dx.doi.org/10.1016/j.clim.2020.108517

Ejemplares similares